LABORATORY RESEARCH PSMA-Targeted Theranostic Nanoplex for Prostate Cancer Therapy Investigators developed a nanoplex platform for theranostic imaging of prostate cancer (PCa). A therapeutic nanoplex containing multimodal imaging reporters was targeted to prostate-specific membrane antigen (PSMA), which is expressed on the cell surface of castrate-resistant PCa. [ACS Nano] Abstract | Press Release Androgen Receptor Antagonism by Divalent Ethisterone Conjugates in Castrate-Resistant Prostate Cancer Cells Researchers illustrated that divalent ethisterone conjugates can antagonize the androgen receptor (AR) via distinct mechanisms of action, establishing new therapeutic strategies for potential applications in AR pharmacology. [ACS Chem Biol] Abstract Comparison of mAbs Targeting Epithelial Cell Adhesion Molecule for the Detection of Prostate Cancer Lymph Node Metastases with Multimodal Contrast Agents: Quantitative Small-Animal PET/CT and Near-Infrared Fluorescence Scientists developed and quantitatively compared dual-labeled monoclonal antibodies (mAbs) of varying affinities against epithelial cell adhesion molecule for both noninvasive and intraoperative detection of metastatic lymph nodes in prostate cancer. [J Nucl Med] Abstract Epigenetic-Induced Repression of MicroRNA-205 Is Associated with MED1 Activation and a Poorer Prognosis in Localized Prostate Cancer Researchers showed that microRNA-205 targets mediator 1 (MED1) for transcriptional silencing in normal prostate cells, leading to reduction in MED1 mRNA levels, and in total and active phospho-MED1 protein. [Oncogene] Abstract Novel Humanized and Highly Efficient Bispecific Antibodies Mediate Killing of Prostate Stem Cell Antigen-Expressing Tumor Cells by CD8+ and CD4+ T Cells Researchers identified a novel bispecific humanized antibody that efficiently re-targets T cells to tumor cells in a strictly antigen-dependent manner and at femtomolar concentrations. [J Immunol] Abstract Design, Synthesis and Evaluation of pH-Dependent Hydrolysable Emetine Analogs as Treatment for Prostate Cancer The N-2′ position of the natural product emetine has been derivatived to thiourea, urea, sulfonamide, dithiocarbamate, carbamate and pH responsive hydrolysable amide analogs. In vitro studies of these analogs in PC3 and LNCaP prostate cancer cell lines showed that the analogs are generally less cytotoxic than emetine. [J Med Chem] Abstract In Vitro and In Vivo Prostate Cancer Metastasis and Chemoresistance Can Be Modulated by Expression of Either CD44 or CD147 Scientists investigated the effects of down-regulation of CD44 or CD147 on the metastatic ability of prostate cancer cells, their docetaxel responsiveness and potential mechanisms involved in vitro and in vivo. [PLoS One] Full Article Growth Differentiation Factor-15 Upregulates Interleukin-6 to Promote Tumorigenesis of Prostate Carcinoma PC-3 Cells Investigators demonstrated that expression of growth differentiation factor-15 induces cell proliferation, invasion, and tumorigenesis of prostate carcinoma PC-3 cells. [J Mol Endocrinol] Abstract Snail Transcription Factor Negatively Regulates Maspin Tumor Suppressor in Human Prostate Cancer Cells Researchers investigated the molecular mechanisms by which Snail increases tumor motility and invasion utilizing prostate cancer cells. [BMC Cancer] Abstract | Full Article CLINICAL RESEARCH A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer This first-in-human, phase I, open-label study assessed safety, pharmacokinetics, and antitumor activity of TRC105 in patients with advanced refractory solid tumors. [Clin Cancer Res] Abstract First-in-Man Application of a Novel Therapeutic Cancer Vaccine Formulation with the Capacity to Induce Multi-Functional T Cell Responses in Ovarian, Breast and Prostate Cancer Patients This phase I clinical study examined the safety and immune activating potential of DPX-0907 in advanced stage breast, ovarian and prostate cancer patients. A total of 23 late stage cancer patients were recruited and were divided into two dose/volume cohorts in a three immunization protocol. [J Transl Med] Abstract | Full Article | Press Release |